Clavel F - Search Results

1

Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay.

Labrosse B, Tourdjman M, Porcher R, LeGoff J, de Lamballerie X, Simon F, Molina JM, Clavel F. Labrosse B, et al. Among authors: clavel f. PLoS One. 2010 Jun 9;5(6):e11036. doi: 10.1371/journal.pone.0011036. PLoS One. 2010. PMID: 20543954 Free PMC article.

2

Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors.

Labrosse B, Labernardière JL, Dam E, Trouplin V, Skrabal K, Clavel F, Mammano F. Labrosse B, et al. Among authors: clavel f. J Virol. 2003 Jan;77(2):1610-3. doi: 10.1128/jvi.77.2.1610-1613.2003. J Virol. 2003. PMID: 12502877 Free PMC article.

3

Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations.

Skrabal K, Trouplin V, Labrosse B, Obry V, Damond F, Hance AJ, Clavel F, Mammano F. Skrabal K, et al. Among authors: clavel f. AIDS. 2003 Apr 11;17(6):809-14. doi: 10.1097/00002030-200304110-00005. AIDS. 2003. PMID: 12660527

4

Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.

Piketty C, Gérard L, Chazallon C, Marcelin AG, Clavel F, Taburet AM, Calvez V, Madelaine-Chambrin I, Molina JM, Aboulker JP, Girard PM; Agence Nationale de Recherche sur le SIDA 107-Puzzle 2 Study Group. Piketty C, et al. Among authors: clavel f. Antivir Ther. 2006;11(2):213-21. Antivir Ther. 2006. PMID: 16640102 Clinical Trial.

5

Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.

Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardière JL, Pacanowski J, Meynard JL, Hance AJ, Clavel F, Mammano F. Labrosse B, et al. Among authors: clavel f. J Virol. 2006 Sep;80(17):8807-19. doi: 10.1128/JVI.02706-05. J Virol. 2006. PMID: 16912327 Free PMC article.

6

Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses.

Nora T, Bouchonnet F, Labrosse B, Charpentier C, Mammano F, Clavel F, Hance AJ. Nora T, et al. Among authors: clavel f. Retrovirology. 2008 Feb 29;5:23. doi: 10.1186/1742-4690-5-23. Retrovirology. 2008. PMID: 18312646 Free PMC article.

7

Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection.

Yu H, Tudor D, Alfsen A, Labrosse B, Clavel F, Bomsel M. Yu H, et al. Among authors: clavel f. Retrovirology. 2008 Oct 16;5:93. doi: 10.1186/1742-4690-5-93. Retrovirology. 2008. PMID: 18925934 Free PMC article.

8

In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations.

Goubard A, Clavel F, Mammano F, Labrosse B. Goubard A, et al. Among authors: clavel f. Antivir Ther. 2009;14(4):597-602. Antivir Ther. 2009. PMID: 19578246

9

Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA).

Su B, Wurtzer S, Rameix-Welti MA, Dwyer D, van der Werf S, Naffakh N, Clavel F, Labrosse B. Su B, et al. Among authors: clavel f. PLoS One. 2009 Dec 30;4(12):e8495. doi: 10.1371/journal.pone.0008495. PLoS One. 2009. PMID: 20041119 Free PMC article.

10

High level of susceptibility to human TRIM5α conferred by HIV-2 capsid sequences.

Takeuchi JS, Perche B, Migraine J, Mercier-Delarue S, Ponscarme D, Simon F, Clavel F, Labrosse B. Takeuchi JS, et al. Among authors: clavel f. Retrovirology. 2013 May 6;10:50. doi: 10.1186/1742-4690-10-50. Retrovirology. 2013. PMID: 23647667 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

178 results

Search Page